New proteasome inhibitors in the treatment of multiple myeloma

AUTOR(ES)

Hungria, Vania Tietsche de Moraes

FONTE

Hematol., Transfus. Cell Ther.

DATA DE PUBLICAÇÃO

15/04/2019

RESUMO

Abstract The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors have produced exciting results, particularly those comparing triplet regimens with standard doublet regimens, with a gain in progression-free survival accompanied by an acceptable safety profile and either similar or better health-related quality of life. New proteasome inhibitors hold the potential to fill unmet needs in multiple myeloma management regarding improvement of clinical outcomes, including delayed progression of disease in high-risk patients. This review summarizes the main pharmacological properties and clinical outcomes of these agents, and discusses their potential to change the whole multiple myeloma therapeutic landscape.

Documentos Relacionados

• Proteasome inhibitors disrupt the unfolded protein response in myeloma cells
• Treatment of multiple myeloma: New drugs raise hope for the future
• Molecular sequelae of proteasome inhibition in human multiple myeloma cells
• Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
• Studies on terrein as a new class of proteasome inhibitors